Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

437 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study.
Gotto AM Jr, Kher U, Chatterjee MS, Liu Y, Li XS, Vaidya S, Cannon CP, Brinton EA, Moon JE, Shah S, Dansky HM, Mitchel Y, Barter P; DEFINE Investigators. Gotto AM Jr, et al. Among authors: barter p. J Cardiovasc Pharmacol Ther. 2014 Nov;19(6):543-9. doi: 10.1177/1074248414529621. Epub 2014 Apr 14. J Cardiovasc Pharmacol Ther. 2014. PMID: 24737712 Clinical Trial.
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.
Cannon CP, Dansky HM, Davidson M, Gotto AM Jr, Brinton EA, Gould AL, Stepanavage M, Liu SX, Shah S, Rubino J, Gibbons P, Hermanowski-Vosatka A, Binkowitz B, Mitchel Y, Barter P; DEFINE investigators. Cannon CP, et al. Among authors: barter p. Am Heart J. 2009 Oct;158(4):513-519.e3. doi: 10.1016/j.ahj.2009.07.028. Am Heart J. 2009. PMID: 19781408 Clinical Trial.
Safety of anacetrapib in patients with or at high risk for coronary heart disease.
Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P; Determining the Efficacy and Tolerability Investigators. Cannon CP, et al. Among authors: barter p. N Engl J Med. 2010 Dec 16;363(25):2406-15. doi: 10.1056/NEJMoa1009744. Epub 2010 Nov 17. N Engl J Med. 2010. PMID: 21082868 Free article. Clinical Trial.
Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease.
Gotto AM Jr, Cannon CP, Li XS, Vaidya S, Kher U, Brinton EA, Davidson M, Moon JE, Shah S, Dansky HM, Mitchel Y, Barter P; DEFINE Investigators. Gotto AM Jr, et al. Among authors: barter p. Am J Cardiol. 2014 Jan 1;113(1):76-83. doi: 10.1016/j.amjcard.2013.08.041. Epub 2013 Oct 4. Am J Cardiol. 2014. PMID: 24188894 Clinical Trial.
Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.
Brinton EA, Kher U, Shah S, Cannon CP, Davidson M, Gotto AM, Ashraf TB, McCrary Sisk C, Dansky H, Mitchel Y, Barter P; DEFINE Investigators. Brinton EA, et al. Among authors: barter p. J Clin Lipidol. 2015 Jan-Feb;9(1):65-71. doi: 10.1016/j.jacl.2014.10.005. Epub 2014 Nov 4. J Clin Lipidol. 2015. PMID: 25670362 Clinical Trial.
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib.
Davidson M, Liu SX, Barter P, Brinton EA, Cannon CP, Gotto AM Jr, Leary ET, Shah S, Stepanavage M, Mitchel Y, Dansky HM. Davidson M, et al. Among authors: barter p. J Lipid Res. 2013 Feb;54(2):467-72. doi: 10.1194/jlr.M032615. Epub 2012 Nov 19. J Lipid Res. 2013. PMID: 23172660 Free PMC article.
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators. LaRosa JC, et al. Among authors: barter p. N Engl J Med. 2005 Apr 7;352(14):1425-35. doi: 10.1056/NEJMoa050461. Epub 2005 Mar 8. N Engl J Med. 2005. PMID: 15755765 Free article. Clinical Trial.
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC; Treating to New Targets Investigators. Barter P, et al. N Engl J Med. 2007 Sep 27;357(13):1301-10. doi: 10.1056/NEJMoa064278. N Engl J Med. 2007. PMID: 17898099 Free article. Clinical Trial.
Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.
HPS3/TIMI55-REVEAL Collaborative Group; Writing Committee; Sammons E, Hopewell JC, Chen F, Stevens W, Wallendszus K, Valdes-Marquez E, Dayanandan R, Knott C, Murphy K, Wincott E, Baxter A, Goodenough R, Lay M, Hill M, Macdonnell S, Fabbri G, Lucci D, Fajardo-Moser M, Brenner S, Hao D, Zhang H, Liu J, Wuhan B, Mosegaard S, Herrington W, Wanner C, Angermann C, Ertl G, Maggioni A, Barter P, Mihaylova B, Mitchel Y, Blaustein R, Goto S, Tobert J, DeLucca P, Chen Y, Chen Z, Gray A, Haynes R, Armitage J, Baigent C, Wiviott S, Cannon C, Braunwald E, Collins R, Bowman L, Landray M; REVEAL Collaborative Group. HPS3/TIMI55-REVEAL Collaborative Group, et al. Among authors: barter p. Eur Heart J. 2022 Apr 6;43(14):1416-1424. doi: 10.1093/eurheartj/ehab863. Eur Heart J. 2022. PMID: 34910136 Free PMC article. Clinical Trial.
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study.
Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM Jr, Carter R, Breazna A, Kastelein JJ, Grundy SM. Waters DD, et al. Among authors: barter p. J Am Coll Cardiol. 2006 Nov 7;48(9):1793-9. doi: 10.1016/j.jacc.2006.07.041. Epub 2006 Oct 17. J Am Coll Cardiol. 2006. PMID: 17084252 Free article. Clinical Trial.
437 results